Myelodysplastic Syndromes

Latest News

Patients with RS-negative low-risk MDS who were relapsed or refractory to or ineligible for ESAs appeared to experience clinical benefit with imetelstat treatment in a post hoc analysis. | Image credit: fotogurmespb - stock.adobe.com
Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

July 1st 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

June 5th 2025

Genetic testing for hereditary forms of solid tumors led to an unsuspected diagnosis of MDS, a recent case report described. | Image Credit: Dr_Microbe - stock.adobe.com
Genetic Testing for Hereditary Cancer Identifies Case of MDS

May 29th 2025

Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com
Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

May 22nd 2025

More News

Image of molecular profiling
December 25th 2022

Distinct Molecular Profiles in Younger vs Older Patients With MDS Identified in New Study

Rose McNulty
The relationship between aging and molecular profiles in myelodysplastic syndromes (MDS) is not well understood, but the findings suggest that different genetic alterations have distinct prognostic implications in different age groups.
blood cells floating around
December 22nd 2022

ICYMI: Top Content From EHA22

AJMC Staff
The 2022 European Hematology Association (EHA22) Congress convened June 9-12, 2022, in Vienna, Austria, and presented cutting-edge findings in hematology, including the potential of artificial intelligence, new treatment combinations in myelofibrosis, and more.
genetic mutations
December 18th 2022

ASXL1 Mutations Associated With Worse Prognosis in MDS and AML

Rose McNulty
A recent meta-analysis found ASXL1 mutations to be independent risk factors for worse overall survival and transformation to acute myeloid leukemia in patients with myelodysplastic syndromes (MDS), as well as worse overall survival in acute myeloid leukemia (AML).
Patrick Reville, MD, MPH
December 16th 2022

Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA

Hayden E. Klein Justina Petrullo
Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
patient with mds
December 12th 2022

Study Identifies Sex-Related Differences in MDS Phenotypes, Genotypes, and Outcomes

Rose McNulty
Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).
blood test
December 9th 2022

Phase 3 Trials in High-Risk MDS Highlight Future Directions

Rose McNulty
A recent review emphasizes a need for novel therapies, summarizes current phase 3 clinical trials, and suggests several considerations for future trials in high-risk myelodysplastic syndromes (MDS).
Key Considerations for Overall MDS Treatment Management
November 15th 2022

Key Considerations for Overall MDS Treatment Management

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.
Future Treatment of MDS
November 15th 2022

Future Treatment of MDS

The expert panel looks to future treatment management for patients with myelodysplastic syndrome.
Unmet Needs in Management of Patients With MDS
November 8th 2022

Unmet Needs in Management of Patients With MDS

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.
Cost-Reduction Strategies in MDS Treatment Pathway
November 8th 2022

Cost-Reduction Strategies in MDS Treatment Pathway

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.
Oral Therapies in MDS Treatment Strategy
November 1st 2022

Oral Therapies in MDS Treatment Strategy

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.
Utilizing Care Pathways in Treatment of MDS
November 1st 2022

Utilizing Care Pathways in Treatment of MDS

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.
Payer Considerations for Selecting Optimal MDS Treatment Approach
October 25th 2022

Payer Considerations for Selecting Optimal MDS Treatment Approach

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.
Hypomethylating Agents Impacting MDS Treatment Landscape
October 25th 2022

Hypomethylating Agents Impacting MDS Treatment Landscape

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.
Supportive Care Needs for Patients with MDS
October 18th 2022

Supportive Care Needs for Patients with MDS

Experts discuss the impact of supportive care in the MDS treatment landscape.
Assessing Treatment Goals for Patients with MDS
October 18th 2022

Assessing Treatment Goals for Patients with MDS

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.
Drivers of Health Resource Management in MDS
October 11th 2022

Drivers of Health Resource Management in MDS

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Challenges Surrounding Access to Care for Patients With MDS
October 11th 2022

Challenges Surrounding Access to Care for Patients With MDS

Expert panelists explore challenges impacting care access for patients with MDS.
Prognostic Models Optimizing MDS Treatment Pathways
October 4th 2022

Prognostic Models Optimizing MDS Treatment Pathways

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.
Incidence and Prevalence of MDS Across Patient Populations
October 4th 2022

Incidence and Prevalence of MDS Across Patient Populations

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.
MDS Impacting Patient Quality of Life
September 27th 2022

MDS Impacting Patient Quality of Life

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
September 27th 2022

Defining Myelodysplastic Syndrome

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Elli Papaemmanuil, PhD.
June 30th 2022

Dr Elli Papaemmanuil Discusses Molecular Profiling of MDS, Use of Precision Medicine

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.
Elli Papaemmanuil, PhD.
June 12th 2022

Dr Elli Papaemmanuil Explains Novel Prognostication, Molecular Classification System for MDS

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.
Expert on MDS
February 7th 2022

Future Management of Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
Expert on MDS
February 7th 2022

Interchangeability Between Oral and IV Agents in HR-MDS

Bruce Feinberg, DO Ryan Haumschild, PharmD, MS, MBA Amer Zeidan, MD Tracey Iraca
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
Expert on MDS
January 31st 2022

Oral Therapy for HR-MDS: Addressing Patient Adherence

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.
Expert on MDS
January 31st 2022

Practical Considerations for the Use of HMAs in Higher-Risk MDS

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.
Experts on MDS
January 31st 2022

Impact of an Oral HMA on the HR-MDS Treatment Landscape

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.
Expert on MDS
January 24th 2022

Higher-Risk MDS: When to Use HMA Therapy or Lenalidomide

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo